Tocagen SNO 2017 Investor & Analyst Breakfast
November 19, 2017
Please contact Clayton Robertson (email@example.com) for additional details and to RSVP.
Tocagen Inc. [TOCA] US$126 MM MCap
Cancer-selective gene therapy company. Lead program Toca 511 and Toca FC are being studied in a registrational Ph 2/3 trial for recurrent high grade glioma (rHGG). A Ph 1 study of Toca 511 and Toca FC showed a near doubling of survival versus historical benchmarks with durable PRs and CRs. [more information]